Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer.
Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer. Breast Cancer. 2014 Nov; 21(6):780-5.